# US 2003/0207380 A1 · Mutant era and test systems for transactivation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207380 A1
- Document ID: US20030207380A1
- Status: Published application
- Kind: A1
- Application number: 10/148,835
- Filed: 2002-10-11
- Published: 2003-11-06
- Earliest claimed: 1999-12-07
- Assignees: Sumitomo Chemical Company, Limited
- Inventors: Koichi Saito; Norihisa Ohe; Hideo Satoh
- Web page: https://patentgrep.com/patent/US20030207380A1

## CPC

- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides in general an artificial cell, an isolated mutant ERα, an isolated polynucleotide encoding the mutant ERα, a method for quantitatively analyzing an activity for transactivation of a reporter gene by a test ERα, a method for screening a mutant ligand dependent transcriptional factor, a method for evaluating an activity for transactivation of a reporter gene by a test ERα, a method for screening a compound useful for treating a disorder of a mutant ERα, a pharmaceutical agent useful for treating an estrogenic disorder of a mutant ERα, use of the mutant ERα, a method for diagnosing a genotype of a polynucleotide encoding a test ERα, a method for diagnosing a genotype of a polynucleotide encoding a test ERα and a method for diagnosing a phenotype of a test ERα.

## Claims

### Claim 1

An artificial cell comprising:
(i) a chromosome which comprises a reporter gene, wherein the reporter gene comprises an ERE, a TATA sequence and a reporter sequence naturally foreign to the ERE; and
(ii) one or more factors selected from the following (ii-a) and (ii-b):
(ii-a) a mutant ERα which has an activity for transactivation of the reporter gene, wherein
in the presence of a partial anti-estrogen and E2 the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen and E2 or
in the presence of a partial anti-estrogen the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen; and
(ii-b) a gene which encodes the mutant ERα.

### Claim 2 (depends on 1)

The artificial cell according to claim 1, wherein the gene of (ii-b) is comprised by the chromosome of (i).

### Claim 3 (depends on 1)

The artificial cell according to claim 1, wherein the gene of (ii-b) is comprised by a vector.

### Claim 4 (depends on 1)

The artificial cell according to claim 1, wherein the partial anti-estrogen is tamoxifen, raloxifene or 4-hydroxytamoxifen.

### Claim 5 (depends on 1)

The artificial cell according to claim 1, wherein the activity is also an activity for transactivation of the reporter gene which is inhibited in the presence of a pure anti-estrogen.

### Claim 6 (depends on 1)

The artificial cell according to claim 1, wherein the mutant ERα has one or more substituted amino acids which confer the activity.

### Claim 7 (depends on 1)

The artificial cell according to claim 1, wherein the mutant ERα has one or more substituted amino acids which confer the activity at one or more relative positions from 303 to 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 8 (depends on 1)

The artificial cell according to claim 1, wherein the mutant ERα has one or more substituted amino acids which confers the activity at one or more relative positions selected from 303, 309, 390, 396, 415, 494, 531 and 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 9 (depends on 1)

The artificial cell according to claim 1, wherein the normal ERα is an ERα having an amino acid sequence shown in SEQ ID: 1.

### Claim 10

An artificial cell comprising:
a chromosome which comprises a reporter gene, wherein the reporter gene comprises an ERE, a TATA sequence and a reporter sequence naturally foreign to the ERE; and
a mutant ERα which activates transcription of a gene downstream from an ERE while exposed to an anti-estrogen which is not antagonistic to an AF1 region of a normal ERα and is antagonistic to an AF2 region of a normal ERα.

### Claim 11 (depends on 10)

The artificial cell according to claim 10, wherein the mutant ERα is one which also activates transcription of the gene downstream from an ERE while bound to E2, wherein the activation is not inhibited by the anti-estrogen which is not antagonistic to an AF1 region of a normal ERα and is antagonistic to an AF2 region of a normal ERα.

### Claim 12

An isolated mutant ERα having:
an activity for transactivation of a reporter gene, the reporter gene comprising an ERE, a TATA sequence and a reporter sequence naturally foreign to the ERE, wherein
in the presence of a partial anti-estrogen and E2 the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen and E2, or
in the presence of a partial anti-estrogen the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen; and
an amino acid sequence of an ERα comprising one or more substituted amino acids at one or more relative positions selected from 303, 309, 390, 396, 494 and 578, or two or more substituted amino acids at two or more relative positions selected from 303, 309, 390, 396, 415, 494, 531 and 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 13 (depends on 12)

The isolated mutant ERα according to claim 12, wherein the substituted amino acid is an arginine at relative position 303, a phenylalanine at relative position 309, a asparaginic acid at relative position 390, a valine at relative position 396, a valine at relative position 494 or a proline at a relative position 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 14 (depends on 12)

The isolated mutant ERα according to claim 12, which is derived from a normal ERα comprising a lysine at relative position 303, a serine at relative position 309, a glycine at relative position 390, a methionine at relative position 396, a glycine at relative position 494 and a seine at relative position 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 15

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 2.

### Claim 16

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 3.

### Claim 17

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 4.

### Claim 18

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 5.

### Claim 19

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 7.

### Claim 20

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 9.

### Claim 21

An isolated mutant ERα having an amino acid sequence shown in SEQ ID: 10.

### Claim 22 (depends on 12)

An isolated polynucleotide encoding the mutant ERα of claim 12.

### Claim 23 (depends on 15)

An isolated polynucleotide encoding the mutant ERα of claim 15.

### Claim 24 (depends on 16)

An isolated polynucleotide encoding the mutant ERα of claim 16.

### Claim 25 (depends on 17)

An isolated polynucleotide encoding the mutant ERα of claim 17.

### Claim 26 (depends on 18)

An isolated polynucleotide encoding the mutant ERα of claim 18.

### Claim 27 (depends on 19)

An isolated polynucleotide encoding the mutant ERα of claim 19.

### Claim 28 (depends on 20)

An isolated polynucleotide encoding the mutant ERα of claim 20.

### Claim 29 (depends on 21)

An isolated polynucleotide encoding the mutant ERα of claim 21.

### Claim 30 (depends on 22)

A vector comprising the polynucleotide of claim 22.

### Claim 31 (depends on 30)

A virus comprising the vector of claim 30.

### Claim 32

A method for quantitatively analyzing an activity for transactivation of a reporter gene by a test ERα, the method comprising:
exposing an artificial cell with a ligand, the artificial cell comprising the test ERα and a chromosome which comprises the reporter gene wherein the reporter gene comprises an ERE, a TATA sequence and a reporter sequence naturally foreign to the ERE; and
measuring a transactivation amount of the reporter gene by the test ERα.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the ligand is a partial anti-estrogen.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the ligand is tamoxifen, raloxifene or 4-hydroxy-tamoxifen.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the ligand is an anti-estrogen which is not antagonistic to an AF1 region and is antagonistic to an AF2 region.

### Claim 36

A method for screening a test ligand dependent transcriptional factor, the method comprising:
exposing an artificial cell with a ligand, the artificial cell comprising a test ligand dependent transcriptional factor and a chromosome which comprises the reporter gene, wherein the reporter gene comprises a receptor responsive sequence cognate with the test ligand dependent transcriptional factor, a TATA sequence and a reporter sequence naturally foreign to the receptor responsive sequence;
measuring a transactivation amount of the reporter gene by the test ligand dependent transcriptional factor;
comparing the transactivation amount of the reporter gene by the test ligand dependent transcriptional factor to a transactivation amount of the reporter gene by a standard; and
selecting the test ligand dependent transcriptional factor wherein the transactivation amount of the reporter gene by the test transactivational amount is different than the transactivation amount of the reporter gene by the standard.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the test ligand dependent transcriptional factor is a mutant ligand dependent transcriptional factor and the standard is a normal test ligand dependent transcriptional factor.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the test ligand dependent transcriptional factor is a test ERα, a test ERβ, a test AR, a test GR, a test PR, a test MR, a test receptor naturally having a lipophilic vitamin as a ligand, a test PPAR or a test TR.

### Claim 39

A method for screening a test ERα, the method comprising:
exposing an artificial cell with a ligand, the artificial cell comprising the test ERα and a chromosome which comprises the reporter gene, wherein the reporter gene comprises an ERE, a TATA sequence and a repolter sequence naturally foreign the ERE;
measuring a transactivation amount of the reporter gene by the test ERα;
comparing the transactivation amount of the reporter gene by the test ERα to a transactivational amount of the reporter gene by a standard; and
selecting the test ERα wherein the transactivation amount of the reporter gene by the test ERα is different than the transactivation amount of the reporter gene by the standard.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the standard is a normal ERα, a normal ERα having an amino acid sequence shown in SEQ ID: 1 or an ERα which phenotype is known.

### Claim 41 (depends on 39)

The method according to claim 39, wherein the ligand is a partial anti-estrogen.

### Claim 42 (depends on 39)

The method according to claim 39, wherein the ligand is tamoxifen, raloxifene or 4-hydroxy-tamoxifen.

### Claim 43

A method for evaluating an activity for transactivation of a reporter gene by a test ERα, the method comprising:
exposing an artificial cell with a ligand, the artificial cell comprising the test ERα and a chromosome which comprises the reporter gene, wherein the reporter gene comprises an ERE, a TATA sequence and a reporter sequence naturally foreign the ERE;
measuring a transactivation amount of the reporter gene by the test ERα; and
comparing the transactivation amount of the reporter gene by the test ERα to a transactivational amount of the reporter gene by a standard.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the standard is a normal ERα, a normal ERα having an amino acid sequence shown in SEQ ID: 1 or an ERα which phenotype is known.

### Claim 45 (depends on 43)

The method according to claim 43, wherein the ligand is a partial anti-estrogen.

### Claim 46 (depends on 43)

The method according to claim 43, wherein the ligand is tamoxifen, raloxifene 4-hydroxy-tamoxifen.

### Claim 47 (depends on 1)

A method for screening a compound useful for treating a disorder of a mutant ERα, the method comprising:
exposing the artificial cell of claim 1 with a test compound;
measuring a transactivation amount of the reporter gene of the artificial cell.

### Claim 48 (depends on 46)

A pharmaceutical agent useful for treating a disorder of a mutant ERα, the agent comprising as an active ingredient a compound screened by the method of claim 46.

### Claim 49 (depends on 12)

Use of the mutant ERα of claim 12 for a receptor binding assay.

### Claim 50

A method for diagnosing a genotype of a polynucleotide encoding a test ERα, the method comprising:
searching in a nucleotide sequence of the polynucleotide encoding the test ERα for one or more valiant codons which encode one or more substituted amino acids in the test ERα wherein the one or more substituted amino acids confer an activity for transactivation of a reporter gene,
in which in the presence of a partial anti-estrogen and E2 the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen and E2 or which in the presence of the partial anti-estrogen the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen, and
in which a chromosome comprises the reporter gene, the reporter gene comprising an ERE, a TATA sequence and a reporter sequence naturally foreign the ERE; and
determining the mutation in the nucleotide sequence of the one or more variant codons by comparing the nucleotide sequence of the one or more variant codons to a nucleotide sequence of one or more corresponding codons in a nucleotide sequence encoding a standard.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the nucleotide sequence of the polynucleotide encoding the test ERα is searched at one or more variant codons which encode an amino acid at one or more relative positions selected from 303, 309, 390, 396, 494 and 578, or an amino acid at two or more relative positions selected from 303, 309, 390, 396, 415, 494, 531 and 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the standard is a normal ERα, a normal ERα having an amino acid sequence shown in SEQ ID: 1 or an ERα which phenotype is known.

### Claim 53

A method for diagnosing a phenotype of a test ERα, the method comprising:
searching in an amino acid sequence of the test ERα for one or more substituted amino acids in the test ERα, wherein the one or more substituted amino acids confer an activity for transactivation of a reporter gene,
in which in the presence of a partial anti-estrogen and E2 the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen and E2 or which in the presence of a partial anti-estrogen the activity is higher than that of a normal ERα in the presence of the partial anti-estrogen, and
in which a chromosome comprises the reporter gene, the reporter gene comprising an ERE, a TATA sequence and a reporter sequence naturally foreign to the ERE; and
determining the mutation in the amino acid sequence of the test ERα by comparing the amino acid sequence of the test ERα to an amino acid sequence of a standard.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the an amino acid sequence of the test ERα is searched at one or more relative positions selected from 303, 309, 390, 396, 494 and 578, or at two or more relative positions selected from 303, 309, 390, 396, 415, 494, 531 and 578, wherein the relative positions are based on a homology alignment to an amino acid sequence shown in SEQ ID: 1.

### Claim 57 (depends on 53)

The method according to claim 53, wherein the standard is a normal ERα, a normal ERα having an amino acid sequence shown in SEQ ID: 1 or an ERα which phenotype is known.
